X4 Pharmaceuticals Stock Fundamentals
XFOR Stock | USD 1.41 0.04 2.76% |
X4 Pharmaceuticals fundamentals help investors to digest information that contributes to X4 Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of XFOR Stock. The fundamental analysis module provides a way to measure X4 Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to X4 Pharmaceuticals stock.
At this time, X4 Pharmaceuticals' Interest Income is relatively stable compared to the past year. As of 03/28/2024, Depreciation And Amortization is likely to grow to about 3.6 M, while Selling General Administrative is likely to drop slightly above 19.2 M. XFOR | Select Account or Indicator |
XFOR Number Of Employees Analysis
X4 Pharmaceuticals' Number of Employees shows the total number of permanent full time and part time employees working for a given company and processed through its payroll.
More About Number Of Employees | All Equity Analysis
2023 | 2024 (projected) | Fixed Asset Turnover | 0.38 | 0.36 | Current Ratio | 5.34 | 5.05 |
Number of Employees | = | Full Time | + | Part Time |
Current X4 Pharmaceuticals Number Of Employees | 93 |
Most of X4 Pharmaceuticals' fundamental indicators, such as Number Of Employees, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, X4 Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Employee typically refers to an individual working under a contract of employment, whether oral or written, express or implied, and has recognized his or her rights and duties. Most officers of corporations are included as employees and contractors are generally excluded.
Competition |
Based on the recorded statements, X4 Pharmaceuticals is currently employing 93 people. This is 99.15% lower than that of the Biotechnology sector and 82.63% lower than that of the Health Care industry. The number of employees for all United States stocks is 99.51% higher than that of the company.
X4 Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining X4 Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare X4 Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across X4 Pharmaceuticals competition to find correlations between indicators driving X4 Pharmaceuticals's intrinsic value. More Info.X4 Pharmaceuticals is rated below average in book value per share category among related companies. It is rated third in working capital category among related companies reporting about 325,291,803 of Working Capital per Book Value Per Share. As of 03/28/2024, Change In Working Capital is likely to grow to about 361.2 K, while Net Working Capital is likely to drop slightly above 89.4 M.. Comparative valuation analysis is a catch-all model that can be used if you cannot value X4 Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for X4 Pharmaceuticals' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the X4 Pharmaceuticals' earnings, one of the primary drivers of an investment's value.XFOR Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses X4 Pharmaceuticals' direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of X4 Pharmaceuticals could also be used in its relative valuation, which is a method of valuing X4 Pharmaceuticals by comparing valuation metrics of similar companies.X4 Pharmaceuticals is currently under evaluation in shares owned by insiders category among related companies.
XFOR Fundamentals
Return On Equity | -1.62 | ||||
Return On Asset | -0.44 | ||||
Current Valuation | 188.41 M | ||||
Shares Outstanding | 167.94 M | ||||
Shares Owned By Insiders | 0.83 % | ||||
Shares Owned By Institutions | 61.37 % | ||||
Number Of Shares Shorted | 14.22 M | ||||
Price To Book | 4.78 X | ||||
Price To Sales | 53.87 X | ||||
Gross Profit | 3 M | ||||
EBITDA | (105.53 M) | ||||
Net Income | (101.17 M) | ||||
Cash And Equivalents | 47.38 M | ||||
Cash Per Share | 0.69 X | ||||
Total Debt | 58.28 M | ||||
Debt To Equity | 1.28 % | ||||
Current Ratio | 2.39 X | ||||
Book Value Per Share | 0.30 X | ||||
Cash Flow From Operations | (96.51 M) | ||||
Short Ratio | 10.52 X | ||||
Earnings Per Share | (0.57) X | ||||
Target Price | 3.26 | ||||
Number Of Employees | 93 | ||||
Beta | 0.44 | ||||
Market Capitalization | 243.51 M | ||||
Total Asset | 147.26 M | ||||
Retained Earnings | (477.9 M) | ||||
Working Capital | 99.21 M | ||||
Z Score | -3.59 | ||||
Net Asset | 147.26 M |
About X4 Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze X4 Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of X4 Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of X4 Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Last Reported | Projected for 2024 | ||
Current Deferred Revenue | 847.5 K | 1.2 M | |
Total Revenue | 0.00 | 0.00 | |
Cost Of Revenue | 2 M | 1 M | |
Ebit Per Revenue | (22.95) | (24.10) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.MSFT | Microsoft | |
GOOG | Alphabet Class C | |
S | SentinelOne |
Check out X4 Pharmaceuticals Piotroski F Score and X4 Pharmaceuticals Altman Z Score analysis. To learn how to invest in XFOR Stock, please use our How to Invest in X4 Pharmaceuticals guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Complementary Tools for XFOR Stock analysis
When running X4 Pharmaceuticals' price analysis, check to measure X4 Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy X4 Pharmaceuticals is operating at the current time. Most of X4 Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of X4 Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move X4 Pharmaceuticals' price. Additionally, you may evaluate how the addition of X4 Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Stocks Directory Find actively traded stocks across global markets | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Commodity Directory Find actively traded commodities issued by global exchanges |
Is X4 Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of X4 Pharmaceuticals. If investors know XFOR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about X4 Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.57) | Return On Assets (0.44) | Return On Equity (1.62) |
The market value of X4 Pharmaceuticals is measured differently than its book value, which is the value of XFOR that is recorded on the company's balance sheet. Investors also form their own opinion of X4 Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is X4 Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because X4 Pharmaceuticals' market value can be influenced by many factors that don't directly affect X4 Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between X4 Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if X4 Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, X4 Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.